Development Of Therapeutic Articles & Analysis: Older
318 news found
Protheragen, a dedicated preclinical research service provider specializing in rare diseases, announces its comprehensive diagnostic development services aimed at empowering researchers in the realm of rare disease research and drug development. ...
Protheragen is proud to release the launch of its comprehensive vaccine development solutions tailored to advance research and development in the field of infectious diseases. ...
To meet the growing needs of the research community, Profacgen’s enhanced AMPs services now offer a more comprehensive suite of solutions aimed at accelerating the discovery and development of these promising therapeutic agents. The company’s updated services provide robust support for the entire peptide development process—from ...
Ace Therapeutics is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. ...
They are essential for the efficient transportation of mRNA to target cells, ensuring that therapeutic mRNA is delivered to the cytoplasm, where it can effectively produce the target protein. ...
Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...
Ace Therapeutics, a preclinical contract research organization (CRO) actively engaged in mental illness research, has announced the launch of its model development services, which aim to revolutionize psychiatric drug research and development. ...
This enhancement aims to offer more precise and comprehensive glycoprotein analysis, catering to the growing demands in the fields of biomedical research, disease biomarker discovery, and therapeutic development. Protein glycosylation, a major post-translational modification, significantly impacts protein folding, stability, and activity. ...
As a CRO company with a wide range of services in basic research, drug development, and preclinical studies, Ace Therapeutics can assist researchers in developing convenient, safe, and effective sustained-release drug delivery systems for the efficient treatment of glaucoma. ...
The vaccine development services from Ace Therapeutics are available to pharmaceutical companies, academic organizations, research institutions, and government agencies seeking to develop vaccines against superbugs. Ace Therapeutics’ team of experts is ready to collaborate with partners to accelerate the ...
The Y-Shape PEG NHS is particularly valuable in drug development and therapeutic protein formulation. It enhances drug stability, prolongs circulation time, and reduces immunogenicity, making it an essential tool for creating more effective and safer biologic drugs. ...
In the realm of pulmonary research, the search to understand complex lung conditions has led to the development of various animal models. Among these, a new murine model from Tsijis et al stands out for its potential to investigate flow-induced pulmonary hypertension (PH) and compensatory lung growth (CLG). This blog outlines this innovative model, its significance, and the method of ...
This premier event, held May 3-7, 2024, at McCormick Place in Chicago, IL, brought together renowned researchers from around the world to share the latest developments in immunology. As an exhibitor at booth #512, Creative BioMart highlighted its extensive range of products designed to support immunology research. ...
ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA. ...
Biopharma PEG, a leading name in the pharmaceutical industry, is proud to announce a groundbreaking advancement in the field of Antibody-Drug Conjugate (ADC) development. The company now offers monodispersed Polyethylene Glycols (PEGs) on a scale ranging from grams to kilograms, and even on a ton scale. ...
(“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (“bYoRNA”) today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (“mRNA”). ...
This service has the potential to transform our understanding of complex protein-protein interactions, opening new avenues for advancements in drug discovery and therapeutic development. Protein-protein interactions serve as the building blocks of various cellular processes, orchestrating critical functions within living organisms. Gaining a deeper ...
Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics Biolojic Tel Aviv to focus on computational design of antibodies; Boston location will focus on drug development Biolojic Design, a unique technology company pioneering computational design of human antibodies to ...
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. ...
$5.5M financing led by Taiho Ventures LLC, with participation of existing investors, including the Series Seed lead, Kizoo Technology Capital GmbH Fresh capital to be employed to get cellvie Series A ready by accelerating the development of the company's technology platform, strengthening the team, and advancing the mitochondria's GMP manufacturing cellvie Inc., a leader in ...